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Abstract
BACKGROUND & AIMS—Hepatocellular carcinoma (HCC) is a heterogeneous tumor that
develops via activation of multiple pathways and molecular alterations. It has been a challenge to
identify molecular classes of HCC and design treatment strategies for each specific subtype.
MicroRNAs (miRNAs) are involved in HCC pathogenesis and their expression profiles have been
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used to classify cancers. We analyzed miRNA expression in human HCC samples to identify
molecular subclasses and oncogenic miRNAs.
METHODS—We performed miRNA profiling of 89 HCC samples using a ligation-mediated
amplification method. Subclasses were identified by unsupervised clustering analysis. We
identified molecular features specific for each subclass using expression pattern (Affymetrix U133
2.0), DNA change (Affymetrix STY Mapping Array), mutation (CTNNB1), and
immunohistochemical (phosphor[p]-Akt, p-IGF-IR, p-S6, p-EGFR, β-catenin) analyses. The roles
of selected miRNAs were investigated in cell lines and in an orthotopic model of HCC.
RESULTS—We identified 3 main clusters of HCCs: the Wnt (32 of 89; 36%), interferon-related
(29 of 89; 33%), and proliferation (28 of 89; 31%) subclasses. A subset of patients with tumors in
the proliferation subclass (8 of 89; 9%) overexpressed a family of poorly characterized miRNAs
from chr19q13.42. Expression of miR-517a and miR-520c (from ch19q13.42) increased
proliferation, migration, and invasion of HCC cells in vitro. MiR-517a promoted tumorigenesis
and metastatic dissemination in vivo.
CONCLUSIONS—We propose miRNA-based classification of 3 subclasses of HCC. Among the
proliferation class, miR-517a is an oncogenic miRNA that promotes tumor progression. There is
rationale for developing therapies that miRNA 517 for patients with HCC.
Keywords
Liver Cancer; Tumor Profiling; OncomiR; On-cogenesis
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death
worldwide and the principal cause of mortality among cirrhotic patients.1 Unlike most solid
tumors, HCC mortality has increased significantly in the 1990 –2005 period,2 most likely
owing to the large number of patients with long-standing hepatitis.3 Only one third of
patients are eligible for curative treatments (resection, liver transplantation, local ablation),
and the multikinase inhibitor sorafenib represents the only approved systemic agent for
advanced cases.4,5
From a molecular perspective, HCC is a highly heterogeneous tumor. Increasing evidence
suggests that its complexity and clinical variability mainly depend on different molecular
alterations that arise during the development and progression of this disease.6 – 8
Translational studies report aberrant activation of different cellular pathways, including IGF,
Ras, Akt/mTOR, and Wnt signaling in HCC.9 –11 Hence, a major clinical challenge is to
identify the predominant molecular mechanisms in distinct HCC molecular classes to select
the best therapeutic option for each individual on the basis of the genomic background of
their tumor.
MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression and
multiple cellular processes including cell differentiation, stem cell maintenance, and
epithelial–mesenchymal transition.12,13 miRNA deregulation represents a common feature
in cancer and can be caused by different mechanisms such as amplification/ deletion,
chromosomal rearrangements, and epigenetic regulation.14 Depending on the genes targeted,
miRNAs can act as tumor suppressors or oncogenes.15 Recent evidence shows abnormal
expression of miRNAs in HCC, including up-regulation of miR-21, miR-221, miR-151, and
down-regulation of Let-7, miR-29, and miR-122.16 –21 Of note, the expression levels of
certain miRNAs (eg, miR-26a) correlate with poor prognosis in HCC.22 Importantly,
miRNA profiling represents a powerful tool to accurately differentiate cancers from normal
tissue and to classify cancer subtypes.23–26 Particularly in HCC, miRNA profiling will
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provide new insights into the molecular complexity of this disease and reveal novel
therapeutic targets.
Herein, we report a miRNA-based molecular classification of hepatitis C virus (HCV)-
related HCC and the discovery of a subset of HCCs overexpressing a family of miRNAs on
chr19q13.41. Specifically, we show that miR-517a on the 19q13.41 locus promotes cell
proliferation and migration in vitro, and induces tumorigenesis in vivo, pointing out its role
as a novel oncomiR in HCC.
Materials and Methods
Human Tissue Samples
Human samples were obtained from the 3 hospitals of the HCC Genomic Consortium:
Mount Sinai Clinical Hospital (New York, NY), Istituto Nazionale dei Tumori (Milan,
Italy), and Hospital Clinic (Barcelona, Spain). The training set included 89 fresh-frozen
HCC samples collected from patients who underwent surgical resection (n = 79) or liver
transplantation (n = 10), which previously were analyzed for messenger RNA (mRNA) and
genomic copy number profiling.27 Formalin-fixed paraffin-embedded tissues of 165 HCCs
(validation set) from patients with different etiologies (HCV, hepatitis B virus [HBV],
alcohol, and others) were used to validate the expression of selected miRNAs. Clinical
characteristics of HCC patients who underwent liver resection (n = 79 and n = 161 for
training and validation sets, respectively) are described in Supplementary Table 1. An
informed consent form was signed by each patient and approval from the Institutional
Review Board was obtained.
RNA Extraction and miRNA, mRNA Genomic Copy Number Profiling
Total RNA from frozen tissues and cell lines was extracted using Trizol Reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. RNA from
formalin-fixed paraffin-embedded sections was extracted as previously described.28 RNA
was quantified using the NanoDrop ND-1000 spectrometer (NanoDrop, Wilmington, DE).
Quality and integrity were measured with a bioanalyzer (Agilent, Palo Alto, CA). The
expression levels of 358 miRNAs were determined using a bead-based amplification method
as previously described.23,29
Genome-wide mRNA and copy number profiling of the training set were performed as
previously described.27 mRNA profiling of the validation set was performed using whole-
genome DNA-mediated annealing, selection, extension, and ligation assay.30,31 Human
Gene 1.0 ST Array (Affymetrix) was used for mRNA profiling of Huh7 cells.
The dataset is available from NCBI’s Gene Expression Omnibus: accession number
GSE20596.
Quantitative Real-Time Polymerase Chain Reaction
Complementary DNA was synthesized using miRNA-specific primers and TaqMan
MicroRNA Reverse Transcription Kit (Applied Biosystems, Austin, TX) according to the
manufacturer’s instructions. miR-23 (constant expression among the samples of the training
set) was used to normalize the expression levels of miR-517a, miR-520g, and miR-516-5p in
the validation set. The ddCt method was used to calculate miRNA expression levels.32 A
median relative expression level greater than 10 for all the 3 was used to define subclass C2
in the validation set. Ct values in samples with detectable levels of miR-517a are listed in
Supplementary Table 2.
TOFFANIN et al. Page 3














Huh-7 cells (Riken Bioresource Center) were grown in Dulbecco’s modified Eagle medium
supplemented with 10% heat-inactivated fetal bovine serum. SNU-449 cells (American
Type Culture Collection) were cultured in RPMI supplemented with 10% heat-inactivated
fetal bovine serum. Cells were maintained at 37°C in a 5% CO2 atmosphere.
Treatment With Demethylase and Histone Deacetylase Inhibitor
Huh7 cells were treated with the demethylating agent 5-aza-2′deoxycytidine 3 μmol/L and
the histone deacetylase inhibitor 4-phenylbutyric acid 3 mmol/L (Sigma-Aldrich, St. Louis,
MO). 5-Aza-2′deoxycytidine was removed after 24 hours whereas 4-phenylbutyric acid was
administered daily for 6 days.
Methylation-Specific Polymerase Chain Reaction
Genomic DNA (n = 6 samples in subclass C2 were available) was treated with sodium
bisulfite using the EpiTect Bisulfite Kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. Sequence primers are listed in Supplementary Table 3.
Polymerase chain reaction (PCR) details are described in the Supplementary Materials and
Methods.
Transfection With Synthetic miRNAs
Details about transfection with synthetic miRNAs are provided in the Supplementary
Materials and Methods.
Proliferation, Migration, and Invasion Assays
Cells were labeled for 3 hours with 1 μCi/mL 3H-thymidine, fixed in 1 N hydrochloride
acid, and lysed in 0.25 N NaOH 24, 48, and 72 hours after transfection. Thymidine
incorporation was measured in a scintillation counter. Migration and invasion assays were
performed using Transwell chambers (8-μmol/L pore size; BD Bioscience, Bedford, MA),
as previously described.33,34
Wound-Healing Assay
Cells were grown to confluence and serum-starved for 24 hours. After pretreatment with
mitomycin C for 3 hours to inhibit proliferation, cell monolayers were wounded with a
sterile tip and maintained in serum-free medium for 24 hours. Images were taken after 0 and
24 hours after wounding on an inverted microscope (×100). Distance measurements between
the 2 edges were performed using ImageJ software (National Institutes of Health, Bethesda,
MD).
miRNA Stable Transfection
The generation of miR-517a stably transfected cells are described in the Supplementary
Materials and Methods.
Orthotopic Model of HCC
Luciferase-tagged Huh7 cells expressed with miR-517a or control vector were injected into
the left liver lobe of nude BALB/C mice (6 – 8 weeks of age). A detailed description of the
method is reported in the Supplementary Materials and Methods. This study was performed
in accordance with the guidelines and regulations from the Institutional Animal Care and
Use Committee.
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In Vivo Imaging System
Mice were anesthetized with isoflurane/oxygen, injected intraperitoneally with luciferin
(150 mg/kg body weight), and placed on the imaging stage. Mice were imaged 1 day after
surgery and once a week for 9 consecutive weeks using the In Vivo Imaging System
(Xenogen Corp, Alameda, CA). Photons emitted from luciferase-expressing cells were
quantified using Living Image software c (Xenogen Corp) and used as an indicator of tumor
growth. At week 10 mice were killed and ex vivo imaging of collected organs was
performed.
Histology
Liver tumors and secondary organs (spleen, stomach, lung, colon, and kidneys) from mice
included in the study were excised, fixed in 4% paraformaldehyde solution, and embedded
in paraffin. Slides (5 μm) were stained with H&E for histologic evaluation.
Bioinformatic Analysis
Unsupervised hierarchical clustering was performed using dChip software (http://
biosun1.harvard.edu/complab/dchip/). A subclass mapping algorithm was used to evaluate
similarities in the global gene-expression profile between the training and validation sets.35
The University of California Santa Cruz Genome Bioinformatics Genome Browser database
(www.genome.ucsc.edu) was used to search for CpG islands in the area surrounding the
chr19q13.41 locus. MethylPrimer software (http://www.urogene.org//methprimer) was used
to design primers for methylation-specific PCR. Gene Set Enrichment Analysis (GSEA) was
used to assess dysregulation of molecular pathways and association with previously reported
molecular subclasses of HCC.36 The Ingenuity Pathway Analysis system (Ingenuity
Systems; available: www.ingenuity.com) was used to analyze signal pathway networks and
canonic pathways from microarray data. The Ingenuity Pathway Analysis generates
interactions between genes and proteins based on findings reported in the literature.
Differential gene expression analysis for the training and validation sets was performed
using the Comparative Marker Selection module of the GenePattern analysis toolkit37 with a
significance threshold of false discovery rate less than 0.05. Analysis of dysregulated genes
in the cell line experiment was performed using Cyber-T software (http://
cybert.microarray.ics.uci.edu/)38 with a significance threshold of posterior probability of
differential expression greater than 0.90 and a P value of less than .01. In silico prediction
analysis for miR-517a genes was performed using TargetScan (www.targetscan.org),
MirBase Sequence Database (www.http://www.ebi.ac.uk), and the DIANA-MicroT
algorithm version 3.0 (http://diana.cslab.ece.ntua.gr/microT).
Statistical Analysis
Comparisons between groups were performed using either the t test or the nonparametric
Mann–Whitney test for continuous variables, and the Fisher exact test for comparison of
proportions. The Pearson coefficient was used to assess correlations between variables.
Survival data from the animal study were plotted with Kaplan–Meier curves and
significance was calculated using the log-rank test. All analyses were performed using the
SPSS package (SPSS 15.0, Chicago, IL) and R statistical package (www.r-project.org).
Results
iRNA-Based Molecular Classification of HCC
The expression levels of 358 human miRNAs were investigated in 89 HCV-related HCC
samples (training set) collected from patients who underwent liver resection or liver
transplantation in the 3 hospitals of the HCC Genomic Consortium: Mount Sinai School of
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Medicine (New York, NY), Istituto Nazionale dei Tumori (Milan, Italy), and Hospital Clinic
(Barcelona, Spain). Unsupervised hierarchical clustering of miRNA data identified 3 main
clusters of HCC, named clusters A (32 of 89; 36%), B (29 of 89; 32%), and C (28 of 89;
31%). The last cluster was divided further into 3 subclusters with clearly distinct miRNA
expression patterns: C1 (15 of 89; 17%), C2 (8 of 89; 9%), and C3 (5 of 89; 6%) (Figure
1A). To define each subclass, we performed a comprehensive genomic analysis by
integrating miRNA data with gene expression analysis, copy number changes, and
assessment of cellular pathway activation by immunohistochemical and mutation analyses
previously performed.27 Interestingly, each subclass was associated to distinct molecular
alterations (Figure 1C). Cluster A was enriched in samples with β-catenin gene mutations
(20 of 32; 62.5%; P < .001) and positive β-catenin immunostaining (16 of 32; 50%; P <.05),
indicating aberrant activation of the β-catenin/Wnt canonical signaling pathway. GSEA was
performed to find significant enrichments of gene signatures from databases of public
domain. As expected, in cluster A we found enrichment of signatures previously associated
with β-catenin mutations: CTNNB1 class by Chiang et al,27 G5-6 by Zucman-Rossi,39 S3
class by Hoshida et al,40 and a significant association with a gene signature predictive of
good survival by Lee et al41 (false discovery rate [FDR] < 0.25) (Supplementary Table 4).
Of note, low serum levels of α-fetoprotein were associated to tumors classified in cluster A
(median serum level, 13 ng/mL; interquartile range, 6.25–23 ng/mL; P < .05). Cluster B was
enriched in samples characterized by expression of interferon-response–related genes (P < .
01).27 Interestingly, these tumors displayed a smaller size (median size, 2.8 cm in diameter)
compared with the other HCCs (median size, 4.4 cm in diameter) (P < .01).
Cluster C was enriched by samples characterized by positive staining for the phosphorylated
forms of IGF-1R (P < .01) and Akt (P < .05), indicating abnormal activation of IGF and
mTOR/Akt/phosphatidylinositol (PI)3K pathways in these tumors. C2 tumors showed
significant up-regulation (median fold change, 8.8; FDR < 0.001) of 23 miRNAs (miR-517a,
miR-517b, miR-517c, miR-520g, miR-520h, miR-519b, miR-519d, miR-516-5p, miR-519a,
miR-520c, miR-520b, miR-520f, miR-526b*, miR-524*, miR-516-1*, miR-526b,
miR-519e, miR-512-3p, miR-522, miR-526a, miR-518f*, miR-518b, and miR-525)
belonging to the largest miRNA cluster ever reported (~100 Kb), located on chr19q13.41
(also referred to as chromosome 19 miRNA cluster, C19MC) (Table 1).42 Among them,
miR-517 was the most up-regulated miRNA (fold change, 23.78; FDR < 0.001). Similarly,
overexpression of another cluster of miRNAs located in the imprinted DLK-DIO3 region on
chromosome 14 (14q32.2-32.31)43 was observed in subclass C3 (median fold change, 6.3;
FDR < 0.02) (Supplementary Table 5). GSEA analysis revealed enrichment of gene
signatures associated to proliferative pathways (Zucman-Rossi’s G123,39 Chiang et al’s27
proliferation) and Lee et al’s41 poor survival in class C1 (FDR < 0.25). Interestingly, C2
tumors showed an enrichment of a Met-positivity signature (FDR < 0.1), which is associated
to oxidative stress responses as well as cell motility, cytoskeletal organization, and
angiogenesis.44 C3 tumors were associated to molecular signatures of aggressive tumors
with poor prognosis including EpCAM-positivity,45 Hoshida et al’s40 S2, Lee et al’s41 poor
survival, Zucman-Rossi’s G123,39 Chiang et al’s27 proliferation, and Kaposi-Novak et al’s44
Met signatures (FDR < 0.25). Molecular correlations showed that C3 tumors were
characterized by p53 mutation (3 of 5; 60%; P < .05) and pAkt staining (4 of 5; 80%; P < .
05). From a clinical perspective, C1 tumors were associated with vascular invasion (P < .05)
and C2 HCCs with poor differentiation degree (P < .05). C3 subclass was characterized by
high levels of α-fetoprotein (median serum levels, 22 × 103 ng/mL; interquartile range, 202–
346 × 103 ng/mL; P < .001), presence of vascular invasion (P < .05), and large tumor size
(median size, 7.5 cm; P < .05).
Finally, we analyzed the expression of previously reported dysregulated miRNAs in our
cohort of samples. Markedly, we found that miR-26a and miR-26b were down-regulated in
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C2 (FDR < 0.001) and C3 (FDR < 0.05) subclasses (Supplementary Figure 1A) and their
low expression levels correlated with poor survival (Supplementary Figure 1B), in
agreement with previous findings.22
Transcriptomic Characterization of C19MC-Expressing HCCs
For a more in-depth analysis we focused on subclass C2, which was characterized by high
expression levels of C19MC miRNAs, a poorly characterized and primate-specific family of
miRNAs. The Ingenuity Pathway Analysis software identified several canonical pathways
significantly related to up-regulated genes including macropinocytosis, focal adhesion
kinase signaling and nuclear factor-κB pathway among others (Supplementary Figure 2A),
whereas few biological processes were related to down-regulated genes (Supplementary
Figure 2B). A network-based analysis revealed a central regulating role of ERK/MEK
signaling, connecting dysregulated genes in C2 subclass (Supplementary Figure 3).
Validation of C19MC miRNA Expression in an Independent Cohort of HCC
We selected 3 miRNAs representative of 3 subfamilies of the cluster (miR-517a, miR-520g,
and miR-516-5p) as markers of C2 subclass, and analyzed their expression levels in an
independent set of 165 formalin-fixed paraffin-embedded HCCs by quantitative real-time
PCR. We observed that 22 HCCs (13%) had median fold changes greater than 2 of all 3
miRNAs compared with other HCCs (Figure 2A). Among them, 7 (4%) were characterized
by very high expression (fold changes, >10) and were considered as C2 subclass. No
significant association between C19MC miRNA expression and etiology was found. Gene
expression patterns associated with the C2 (C19MC) classification was significantly similar
between the training and validation sets, supporting the conclusion that the 3 miRNA-based
classification of subclass C2 recapitulated the same biological entity of HCC tumors (Figure
2B) (P < .01).
Mechanisms of C19CM miRNAs Overexpression
Next, we sought to determine which molecular mechanisms could be involved in the
aberrant overexpression of C19MC miRNAs in subclass C2 of our training set. Only 1 of 8
samples (12.5%) showed genomic copy number gains of C19MC (mean copy numbers in 1
Mb surrounding 19q13.41 region, 2.97) (Figure 3A, sample 8). The presence of a CpG
island located 15 kb upstream of the C19MC locus suggested that epigenetic mechanisms
could be implicated in the regulation of 19q13.41 miRNAs expression (Figure 3B). To show
the functional significance of the methylation status of this CpG island in the regulation of
C19MC miRNAs we exposed the C19MC-negative Huh7 cells to the demethylating agent 5-
aza-2′deoxycytidine and the histone deacetylase inhibitor 4-phenylbutyric acid, and
evaluated miR-517a levels by quantitative real-time PCR. Interestingly, miR-517a
expression was massively increased after treatment (fold change, 51; P < .001) (Figure 3C),
along with demethylation of CG sites in the CpG island upstream of the cluster
(Supplementary Figure 3). Consistent with this finding, we detected the presence of un-
methylated sequences of the CpG island upstream of the C19MC cluster in 4 of 6 (67%)
human samples belonging to subclass C2 (Figure 3D).
Oncogenic Activity of miR-517a and miR-520c In Vitro
To test whether members of the C19MC family showed a functional role in HCC, we
investigated the role of C19MC miRNAs in the Huh7 cells, which derive from a well-
differentiated and nonmetastatic human HCC46 and SNU-449 cell line, which has been
established by a single HCC with perinodular extensions. We focused on miR-517a and
miR-520c, representing 2 different sub-families within the C19MC cluster. Both miRNAs
were expressed at very low levels in Huh7 and SNU-449 cells (Supplementary Figure 5A).
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Interestingly, enhanced expression of either miR-517a or miR-520c but not a control
oligonucleotide promoted cell proliferation (P < .05) (Figure 4A) and conferred a potent
migratory (P < .001) and invasive phenotype (P < .05) to Huh7 cells across Transwell
chambers uncoated or coated with Matrigel, respectively (Figure 4B and C). In addition,
expression of both miRNAs increased the migratory capability of Huh7 cells in a wound-
healing assay (P < .002) (Figure 4D). Similar results were obtained using SNU-449 cells,
confirming the oncogenic role of miR-517a and miR-520c (Supplementary Figure 5B–E).
Biological and Clinical Relevance of miR-517a Overexpression
For further analyses, miR-517a was selected because of the novelty and magnitude of its
expression in HCC. To assess the biological relevance of miR-517a expression, we
generated a stably miR-517a-transduced Huh7 cell line using a lentiviral vector system.
Microarray analysis of miR-517a– expressing Huh7 cells was performed to interrogate the
effects of miR-517 overexpression on the global molecular status of HCC cells. We found
433 up-regulated and 153 down-regulated genes in Huh7 cells transduced with miR-517a
compared with control vector (P < .005) (Supplementary Tables 6 and 7). Ingenuity Pathway
Analysis of microarray data revealed the presence of 2 main networks induced by miR-517a
(Supplementary Figure 6), one related to the nuclear factor-κB complex and the other
associated with the MAPK/ERK signaling. DNA replication and cell cycle represented the
most relevant biological functions induced in miR-517a–transduced cells (FDR < 0.001)
(Supplementary Table 8).
To identify potential target genes of miR-517a we performed an in silico prediction analysis
using TargetScan, MirBase Sequence Database, and the DIANA-MicroT algorithm version
3.0. Among these genes only 6 were down-regulated (CACNA2D3, CTLA4, GPR20,
OR4X1, SLC7A3, and TNIP1) and 3 were up-regulated (IFI35, MCTS1, and NRCAM) in
miR-517a–transduced cells. Interestingly, GSEA showed enrichment of the 3 up-regulated
genes in C2-tumors (FDR < 0.2).
From a clinical perspective, high levels of miR-517a were associated with the presence of
satellite nodules around the main tumor both in the training and validation sets (P < .05).
miR-517a Promotes Tumorigenesis and Metastatic Dissemination In Vivo
Finally, we aimed to investigate whether miR-517a might drive tumorigenesis in vivo using
a bioluminescence imaging system to allow sensitive detection of tumor growth in an
orthotopic model of HCC. Importantly, we found that miR-517a strongly promoted the
tumorigenic potential of Huh7 cells in vivo by inducing the development of aggressive liver
tumors in 7 of 10 (70%) mice compared with control vector (1 of 11; 9%) (P < .001) (Figure
5A and B). As a consequence, mice injected with miR-517a– expressing cells showed
reduced survival compared with control mice (P < .05) (Figure 5C). Interestingly, miR-517a
promoted the formation of different size nodules, indicating intrahepatic dissemination from
the primary site of injection (Figure 5D). Ex vivo analysis of dissected organs showed the
presence of extrahepatic metastases to secondary organs (lungs and kidneys) in 4 mice
injected with miR-517a–transduced cells (4 of 10; 40%) (Figure 6A). Histologic evaluation
showed the presence of vascular invasion in liver sections collected from miR-517a tumors
and confirmed the presence of multiple metastatic nodules in the lung and perirenal soft
tissue (Figure 6B).
Discussion
This study provides compelling evidence that miR-517a, which belongs to the large C19MC
miRNA cluster, acts as a novel oncomiR in HCC. Previous studies showed that C19MC
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miRNAs are expressed in undifferentiated tissues including placenta, human embryonic, and
hematopoietic stem cells.47– 49 In particular, the expression of different members of the
C19MC cluster (miR-520g, miR-518b, miR-518c, miR-512-3p, miR-524*) has been shown
to be strongly down-regulated during differentiation of hematopoietic embryonic stem cells,
indicating their role in stem cell maintenance.47 Recently, Li et al50 reported overexpression
of C19MC miRNAs in a subgroup of aggressive brain tumors owing to genomic
amplification of the chr19q13.41 locus. Furthermore, chromosomal rearrangements
involving the 19q13.41 locus were reported in a subgroup of thyroid adenomas.51 In our
study we observed that genomic amplification poorly contributed to the overexpression of
C19MC miRNAs in HCC, whereas aberrant hypomethylation was more frequent. Therefore,
our analysis confirms previous findings indicating that epigenetic changes could regulate the
expression of C19MC miRNAs.52,53
Importantly, the study by Huang et al33 showed that overexpression of miR-520c was
sufficient to promote invasion and metastasis of breast cancer cells, indicating that members
of the C19MC family could be involved in cell motility. Consistent with this finding, our
data indicate that enhanced expression of either miR-517a or miR-520c promotes a more
malignant phenotype of HCC cells. To further confirm this finding, we tested the function of
miR-517a in vivo using an orthotopic mouse model of HCC to more closely mimic HCC in
human beings. The major utility of orthotopic cancer models are their ability to recapitulate
the metastatic potential and patterns seen in human cancer. Previous studies have suggested
that Huh7 cells do not induce the development of liver tumors in vivo,54 a finding that we
also observed in our control animals. In contrast, however, overexpression of miR-517a in
orthotopic Huh7 cells greatly promoted their tumorigenic potential and induced the
development of large and invasive liver tumors. Although specific target genes for
miR-517a still need to be discovered, our bioinformatic analysis revealed that miR-517a
induced perturbations of the MAPK and nuclear factor-κB pathways, in line with the
findings reported by Luo et al.55 Interestingly, macropinocytosis represented the most
significant biological process associated to up-regulated genes in C2 tumors. The process of
macropinocytosis contributes to both growth and motile processes of cells,56 providing
further evidence linking miR-517a with cell proliferation and migration. Altogether, our
results indicate that miR-517a is involved in HCC pathogenesis and likely represents a
promising molecular target for new therapies. Although miR-517a–overexpressing HCCs
represent only a small percentage of cases (approximately 9%–10% of cases), strategies
targeting miR-517a could prove beneficial and optimal in terms of personalized
management of patients.
Recent reports suggest that miRNA-based therapy for the treatment of cancer is feasible and
potentially effective. MiR-26a and Let-7 have been identified as promising candidates
because of their relevance in cancer pathogenesis.19,57 The continuous discovery of novel
oncomiRs and tumor suppressor miRNAs represent an exciting and relevant area of
progress. Chemically modified cholesterol-conjugated oligonucleotides, termed antagomirs,
have been developed to inhibit the expression of oncogenic miRNAs, and their use currently
is under investigation in preclinical studies.58 To date, preliminary animal studies have
indicated that miRNA-based therapy is safe and nontoxic, although further evaluation is
required before assessing its safety in human beings.59 In this context, our study provides a
clear rationale for testing antago-mir-based approaches targeting miR-517a and other
potential oncogenic members of the C19MC family in pre-clinical models of HCC.
(Supplementary Figure 4).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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miRNA-based molecular classification of HCC. (A) Heat map showing unsupervised
hierarchical clustering of 89 HCV-related HCCs based on the expression levels of 358
human miRNAs. MiRNAs are in row, samples are in column. High and low expression
levels are represented in red and blue, respectively. Molecular subclasses (A, B, C1, C2, C3)
are indicated by colored bars. Up-regulation of C19MC family in subclass C2 is shown.
Immunostaining for pEGFR, pAkt, pS6, pIGF1R, β-catenin localization, and the mutation
status of TP53 and CTNNB1 genes are indicated in different colors (grey, positive; black,
negative; white, missing value). Overlaps with transcriptomic-based molecular classes
previously reported by our group are shown. Different colors correspond to distinct
molecular classes. Chiang et al’s27 classification includes CTNNB1 class (blue),
proliferation class (green), interferon-related class (pink), the Poly7 (polysomy of
chromosome 7) class (orange), and unannotated samples (brown). Hoshida et al’s40
classification includes S1 class (blue), S2 class (green), and S3 class (yellow). (B) Summary
of the proposed miRNA-based molecular classification of HCC. AFP, α-fetoprotein; VI,
vascular invasion.
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Validation of subclass C2 in an independent set of HCC. (A) Relative expression levels of
miR-517a, miR-520g, and miR-516-5p were used as molecular surrogates of subclass C2
and evaluated in 165 formalin-fixed paraffin-embedded (FFPE) HCCs. High and low
expression levels are indicated in gradient scale boxes. Black boxes, missing values. (B)
Subclass association matrix for subclass C2 and other classes (non-C2) in the training
(frozen tissues) and validation (FFPE sections) sets. Subclasses C2 in both HCC sets
characterized by different tissue origin were significantly associated.
TOFFANIN et al. Page 15














Molecular mechanisms involved in C19MC miRNAs overexpression. (A) Inferred copy
number of chr19 for each sample in subclass C2. C19MC locus is indicated by an arrow.
One sample (indicated by a red box) showed copy gain in the q arm of chr19 (inferred copy
numbers in the 1 Mb surrounding 19q13.41 region, 2.97). (B) Genomic localization of
C19MC miRNAs on chr19. A CpG island is located 15 kb upstream of the cluster. (C)
Expression level of miR-517a after treatment with 5-aza-2′deoxycytidine (5-AZA-CDR)
and 4-phenylbutyric acid (PBA) in Huh7 cells compared with untreated cells. Results are
expressed as fold changes ± standard error of the mean. (D) Methylation-specific PCR of the
CpG island located upstream of the C19MC locus. Presence of PCR product indicates
methylated (lane M) or unmethylated (lane U) alleles. Huh7 (DNA from Huh7 without
bisulfite conversion), negative control; SsI-Huh7 (enzymatically methylated DNA), positive
control. HCC: subclass C2 (n = 6 samples); normal, 1 representative normal liver.
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miR-517a and miR-520c promote cell proliferation, migration, and invasion in vitro. (A)
Proliferation assay after transfection with control oligonucleotide, miR-517a, or miR-520c
in Huh7 cells. Results are expressed as a percentage of 3H-thymidine incorporation (counts
per million) ± standard error of the mean compared with control. (B) Transwell migration
assay. Cells that migrated from the upper well of a Transwell chamber into the lower well
were stained and counted. Magnification, ×100. (C) Cell invasion assays. Inserts coated with
Matrigel were used to investigate the invasive potential of miR-517a and miR-520c
transfected cells. Magnification, ×100. (D) Wound-healing assay. Cell monolayers were
scratched and images were taken 0 and 24 hours after wounding. Results are expressed as
distance (in μm) between the 2 edges ± standard error of the mean. Magnification, ×100.
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miR-517a promotes tumorigenesis in vivo. (A) Luciferase-tagged Huh7 cells transduced
with miR-517a or control vector were injected into the left lobe of the liver of nude mice.
Representative images taken at day 1, and at 2, 4, 6, and 8 weeks are displayed. (B)
Incidence of liver tumors in mice injected with Huh7 transduced with miR-517a or control
vector. (C) Kaplan–Meier curves representing the decrease in survival of mice injected with
miR-517a–expressing Huh7 compared with control-Huh7. (D) Multiple tumor nodules were
observed in liver of mice administered with miR-517a–transduced Huh7.
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miR-517a induces metastatic dissemination of Huh7 cells in vivo. (A) Bioluminescent
imaging of dissected organs showed the presence of large liver tumors and metastases in
lungs and kidneys of mice injected with miR-517a– expressing cells. Representative images
are shown. (B) Histologic analysis showed the presence of vascular invasion and metastases
in distant organs in mice administered with miR-517a– expressing Huh7.
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Table 1
C19MC miRNAs Up-Regulated in Subclass C2
Probe ID miRNA FDR Fold change
JLA180 miR-517a, b, c 0.00 23.78
JLA176 miR-520g, h 0.00 17.13
JLA161 miR-519b 0.00 15.61
JLA29 miR-519d 0.00 14.89
JLA27 miR-516-5p 0.00 13.81
JLA7 miR-519a 0.00 12.44
JLA17 mir-520c, b, f 0.00 12.13
JLA160 miR-526b* 0.00 10.98
JLA170 miR-524* 0.00 8.79
JLA71 mir-516-1* 0.00 7.47
JLA159 miR-526b 0.00 6.93
JLA154 miR-519e 0.00 6.51
JLA150 miR-512-3p 0.00 6.13
JLA2 miR-522 0.00 5.56
JLA164 miR-526a,518f* 0.00 4.51
JLA28 miR-518b 0.00 4.32
JLA162 miR-525 0.00 3.80
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